Financial reports
10-K
2023 FY
Annual report
14 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
26 Apr 23
10-K
2022 FY
Annual report
16 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
11 May 22
10-K
2021 FY
Annual report
29 Mar 22
Current reports
8-K
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
14 Mar 24
8-K
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024
8 Jan 24
8-K
Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
9 Nov 23
8-K
Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules
26 Oct 23
8-K
Monte Rosa to receive an upfront payment of $50 million and potential future payments exceeding $2 billion
17 Oct 23
8-K
Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
10 Aug 23
8-K
Departure of Directors or Certain Officers
26 Jul 23
8-K
Amendments to Articles of Incorporation or Bylaws
14 Jun 23
8-K
Monte Rosa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update
11 May 23
8-K
Departure of Directors or Certain Officers
23 Mar 23
Registration and prospectus
S-8
Registration of securities for employees
14 Mar 24
424B5
Prospectus supplement for primary offering
26 Oct 23
S-8
Registration of securities for employees
16 Mar 23
S-3
Shelf registration
1 Jul 22
S-8
Registration of securities for employees
29 Mar 22
S-8
Registration of securities for employees
25 Jun 21
424B4
Prospectus supplement with pricing info
25 Jun 21
S-1MEF
Registration of additional securities for an S-1
23 Jun 21
8-A12B
Registration of securities on exchange
21 Jun 21
S-1/A
IPO registration (amended)
21 Jun 21
Other
EFFECT
Notice of effectiveness
14 Jul 22
CORRESP
Correspondence with SEC
11 Jul 22
UPLOAD
Letter from SEC
8 Jul 22
EFFECT
Notice of effectiveness
24 Jun 21
SEC STAFF
SEC staff action: Order
23 Jun 21
CERT
Certification of approval for exchange listing
22 Jun 21
CORRESP
Correspondence with SEC
21 Jun 21
CORRESP
Correspondence with SEC
21 Jun 21
CORRESP
Correspondence with SEC
21 Jun 21
UPLOAD
Letter from SEC
15 Jun 21
Ownership
SC 13G
BAKER BROS. ADVISORS LP
14 Feb 24
SC 13G/A
Cormorant Asset Management, LP
14 Feb 24
SC 13G/A
BlackRock Inc.
14 Feb 24
SC 13G/A
PRICE T ROWE ASSOCIATES INC /MD/
14 Feb 24
SC 13G/A
Avoro Capital Advisors LLC
14 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
4
Markus Warmuth
4 Jan 24
4
Owen B. Wallace
4 Jan 24
4
Jullian G Jones
4 Jan 24
4
Filip Janku
4 Jan 24